A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer.

CONCLUSIONS: The combination of ixabepilone and cetuximab was active and had acceptable toxicity. The efficacy results are similar to single-agent ixabepilone and gemcitabine-based combination therapies in patients with advanced pancreatic cancer. Exploratory analyses suggest a trend toward improved survival for patients who experienced rash. PMID: 23112883 [PubMed]
Source: Gastrointestinal Cancer Research - Category: Cancer & Oncology Tags: Gastrointest Cancer Res Source Type: research